Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma
Condition(s):Pheochromocytoma; ParagangliomaLast Updated:October 7, 2022Recruiting
Include Studies Not Open or Pending
Condition(s):Pheochromocytoma; ParagangliomaLast Updated:October 7, 2022Recruiting
Condition(s):Collecting Duct CarcinomaLast Updated:January 18, 2024Not yet recruiting
Condition(s):Renal Cancer; Kidney Cancer; Renal Cell Carcinoma; Inferior Vena Cava ThrombosisLast Updated:January 30, 2024Recruiting
Condition(s):Metastatic Renal Cell CarcinomaLast Updated:May 8, 2023Recruiting
Condition(s):Hepatobiliary Neoplasm; Liver Neoplasm; Biliary Tract NeoplasmsLast Updated:March 29, 2023Recruiting
Condition(s):Papillary Renal Cell Carcinoma Type 2Last Updated:January 25, 2024Recruiting
Condition(s):Renal Carcinoma MetastaticLast Updated:January 6, 2021Recruiting
Condition(s):Carcinoma, Renal Cell; Fumarate Hydratase Deficiency; ImmunotherapyLast Updated:October 10, 2023Recruiting
Condition(s):Clear Cell Kidney Cancer; Kidney Cancer; Kidney Cancer With PBRM1/BAP1/VHL/SETD2 MutationsLast Updated:July 12, 2023Available
Condition(s):MelanomaLast Updated:February 28, 2024Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.